Core Viewpoint - Alpha Cognition Inc. is actively engaging in commercialization efforts and research initiatives to enhance the adoption of its therapies for neurodegenerative diseases, particularly through participation in a virtual fireside chat hosted by Titan Partners [1][2]. Company Overview - Alpha Cognition Inc. is a commercial-stage biopharmaceutical company focused on developing treatments for neurodegenerative diseases, including Alzheimer's disease and cognitive impairment associated with mild traumatic brain injury (mTBI) [2][9]. - The company is dedicated to addressing the unmet medical needs in these areas, where currently no approved treatment options exist [2]. Product Information - ALPHA-1062, marketed as ZUNVEYL, is an FDA-approved new generation acetylcholinesterase inhibitor designed for the treatment of Alzheimer's disease, with minimal gastrointestinal side effects expected [3]. - ZUNVEYL's active metabolite uniquely binds to neuronal nicotinic receptors, particularly the alpha-7 subtype, which is associated with cognitive enhancement [3]. - The product is also being developed in combination with memantine for moderate to severe Alzheimer's dementia and as a sublingual formulation for cognitive impairment with mTBI [3]. Upcoming Events - Alpha Cognition will participate in a virtual fireside chat on December 2, 2025, featuring CEO Michael McFadden, focusing on commercialization strategies and research initiatives [2]. - The company is set to report its third quarter 2025 financial results and provide a business update on November 13, 2025, after market close [9].
Alpha Cognition to Participate in Virtual Fireside Chat Hosted by Titan Partners